Ameriprise’s ProQR Therapeutics PRQR Stock Holding History

Ameriprise’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,200	Closed	-$94K	–	4030
2021 Q3	$94K	Sell	11,200 -1,200	-10%	-$7.84K	﹤0.01%	3784
2021 Q2	$84K	Buy	+12,400	New	+$80K	﹤0.01%	3836

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ameriprise's PRQR Position: Q4 2021 in Review

Ameriprise sold out of ProQR Therapeutics (PRQR) in Q4 2021, closing a stake of 11,200 shares — an estimated $94K sold.

Ameriprise first reported a position in PRQR in Q2 2021 and held it in 2 quarters. The position peaked at $94K in Q3 2021. 74 funds tracked by Wall St. Rank hold PRQR as of Q4 2021.

Ameriprise reported no remaining ProQR Therapeutics position as of Q4 2021 after selling out during the quarter.
Ameriprise sold 11,200 ProQR Therapeutics shares in Q4 2021, an estimated $94K.
Ameriprise first reported a position in ProQR Therapeutics in Q2 2021 and held it in 2 quarters.
Ameriprise's ProQR Therapeutics position peaked at $94K in Q3 2021.
74 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2021.

Based on Ameriprise's 13F filing for Q4 2021, filed 14 Feb 2022.